Brighton Jones LLC’s PTC Therapeutics PTCT Stock Holding History

Brighton Jones LLC’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,628	Closed	-$226K	–	1053
2025 Q2	$226K	Buy	+4,628	New	+$220K	0.01%	832

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brighton Jones LLC's PTCT Position: Q3 2025 in Review

Brighton Jones LLC sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 4,628 shares — an estimated $226K sold.

Brighton Jones LLC first reported a position in PTCT in Q2 2025 and held it in 1 quarter. The position peaked at $226K in Q2 2025. 293 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

Brighton Jones LLC reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
Brighton Jones LLC sold 4,628 PTC Therapeutics shares in Q3 2025, an estimated $226K.
Brighton Jones LLC first reported a position in PTC Therapeutics in Q2 2025 and held it in 1 quarter.
Brighton Jones LLC's PTC Therapeutics position peaked at $226K in Q2 2025.
293 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on Brighton Jones LLC's 13F filing for Q3 2025, filed 14 Oct 2025.